We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The larger clinical opportunity is proactive identification of patients eligible for proven but under-used therapies, including [guideline-directed medical therapies], device-based therapies, advanced HF evaluation and hemodynamic monitoring. Realizing that opportunity will depend less on detection accuracy alone than on workflow, access, governance and multidisciplinary follow-up infrastructure. AI-enabled chart review should therefore be viewed as a scalable abstraction layer for evidence generation and implementation, with clinician oversight and equitable deployment determining whether technical gains translate into better HF outcomes.”
No takes yet. Share an insight, caveat, or question.
Hamilton et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: